Lymphocytic Gastritis (Collagenous Gastritis)

1. Executive Overview: Understanding Lymphocytic Gastritis

Lymphocytic gastritis (LG) is a distinct, relatively rare form of chronic gastritis characterized by a significant infiltration of mature lymphocytes into the gastric surface and foveolar epithelium. When this condition is associated with a subepithelial collagen band, it is specifically referred to as Collagenous Gastritis (CG).

Clinically, this condition represents a diagnostic challenge because patients often present with non-specific dyspeptic symptoms that mimic common conditions like peptic ulcer disease or functional dyspepsia. However, histologically, it is distinct. The presence of more than 25–30 intraepithelial lymphocytes (IELs) per 100 epithelial cells—in the absence of Helicobacter pylori or other infectious triggers—is the hallmark diagnostic marker. While often associated with systemic autoimmune conditions, such as Celiac disease or lymphocytic colitis, LG requires a specialized multidisciplinary approach to ensure accurate diagnosis and long-term management.

2. Pathophysiology, Etiology, and Risk Factors

The exact pathogenesis of lymphocytic gastritis remains a subject of intense clinical research. Unlike common forms of gastritis driven by H. pylori or NSAID use, LG is believed to be an immune-mediated mucosal inflammatory process.

The Pathophysiological Mechanism

The infiltration of lymphocytes into the surface epithelium suggests a T-cell-mediated immune response. In cases of collagenous gastritis, the thickening of the subepithelial collagen band (greater than 10 micrometers) is thought to be a secondary response to chronic mucosal injury or a unique inflammatory cytokine profile. This thickening impairs the normal barrier function of the stomach lining, potentially leading to protein-losing gastropathy and malabsorption.

Etiology and Associations

While many cases are idiopathic, several high-risk associations have been identified:
* Celiac Disease: A strong correlation exists between lymphocytic gastritis and gluten-sensitive enteropathy.
* Autoimmune Disorders: Patients with lymphocytic colitis, collagenous colitis, and autoimmune thyroiditis show a higher incidence rate.
* Infections: Although H. pylori is traditionally associated with neutrophilic gastritis, it can occasionally trigger a lymphocytic response.
* Medications: Certain drugs, particularly ticlopidine and some non-steroidal anti-inflammatory drugs (NSAIDs), have been implicated in triggering the condition.

Risk Factors Table

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of lymphocytic gastritis is highly variable. Many patients are entirely asymptomatic, with the condition discovered incidentally during endoscopy for other indications. However, when symptomatic, the presentation often includes:

• Epigastric Pain: A burning or gnawing discomfort in the upper abdomen.
• Dyspepsia: Chronic indigestion, bloating, and early satiety.
• Nausea and Vomiting: Often persistent, particularly in cases of collagenous gastritis.
• Weight Loss and Anemia: In severe cases, particularly with collagenous gastritis, the thickening of the collagen band leads to poor nutrient absorption and iron-deficiency anemia.
• Protein-Losing Gastropathy: This can result in peripheral edema due to hypoalbuminemia.

4. Standard Diagnostic Evaluation & Workup

The diagnosis of lymphocytic gastritis cannot be made through clinical symptoms alone. It is a histological diagnosis requiring a high index of suspicion from the endoscopist and pathologist.

Endoscopic Findings

During an upper endoscopy (EGD), the gastric mucosa may appear normal, or it may exhibit:
* Varioliform Gastritis: Multiple small, raised nodules or erosions, often described as "cobblestoning."
* Erythema and Edema: Generalized redness and swelling of the gastric folds.
* Atrophy: In advanced, long-standing cases.

Diagnostic Criteria (The Gold Standard)

1. Biopsy: Multiple biopsies from the antrum and the body of the stomach are mandatory.
2. Histopathology: The pathologist must quantify the IELs. A count exceeding 25–30 lymphocytes per 100 epithelial cells is diagnostic.
3. Special Stains: Trichrome staining is required to identify the subepithelial collagen band, which confirms the diagnosis of Collagenous Gastritis.
4. Exclusion: The clinician must rule out H. pylori via immunohistochemistry or urea breath testing.

5. Therapeutic Interventions

There is no single "standard of care" for lymphocytic gastritis because the condition is rare and often secondary to other systemic issues. Treatment is generally tailored to the underlying pathology.

Pharmacotherapy

• Corticosteroids: Budesonide is frequently used in cases of collagenous gastritis due to its high topical potency and low systemic bioavailability.
• Proton Pump Inhibitors (PPIs): Used to manage gastric acid secretion and alleviate dyspeptic symptoms, although they do not treat the underlying lymphocytic infiltration.
• Gluten-Free Diet: If biopsy confirms an association with Celiac disease, a strictly enforced gluten-free diet is the first-line treatment and often leads to the resolution of gastric symptoms.
• Discontinuation of Triggering Agents: If the patient is on ticlopidine or certain NSAIDs, immediate cessation is required.

Surgical and Long-term Management

Surgery is rarely indicated unless there are complications such as severe gastric outlet obstruction or intractable bleeding. Long-term prognosis is generally favorable, provided the underlying trigger is addressed. Patients require periodic endoscopic surveillance to monitor for mucosal healing and to ensure that the condition does not progress to gastric atrophy or, in very rare instances, malignancy.

6. Frequently Asked Questions (FAQ)

1. Is lymphocytic gastritis a form of cancer?
No, it is a chronic inflammatory condition. It is not malignant, although persistent inflammation requires monitoring.

2. Is collagenous gastritis the same as lymphocytic gastritis?
They are related. Collagenous gastritis is a specific subset of lymphocytic gastritis characterized by a thickened collagen band under the stomach lining.

3. Can diet cure this condition?
If the gastritis is linked to Celiac disease, a gluten-free diet is often curative. In idiopathic cases, diet may help manage symptoms but may not resolve the inflammation.

4. How is it diagnosed definitively?
It requires an upper endoscopy with multiple tissue biopsies that are examined by a pathologist to count intraepithelial lymphocytes.

5. What is the role of H. pylori in this condition?
H. pylori is usually absent in primary lymphocytic gastritis. If present, it must be treated, but the lymphocytic infiltration often persists even after the bacteria are cleared.

6. Are there long-term complications?
If left untreated, severe cases (especially collagenous gastritis) can lead to protein-losing gastropathy, iron deficiency, and chronic anemia.

7. Is this condition permanent?
Many cases can be managed or go into remission, but it is considered a chronic condition that may require long-term follow-up.

8. Do I need to see a specialist?
Yes, you should be managed by a gastroenterologist, ideally one with experience in inflammatory gastric disorders.

9. Can medications cause this?
Yes, certain medications like NSAIDs and specific anti-platelet drugs have been linked to the development of lymphocytic gastritis.

10. Is it contagious?
No, lymphocytic gastritis is not contagious and cannot be spread from person to person.

Disclaimer: This guide is for educational purposes and does not constitute medical advice. Always consult with a licensed gastroenterologist for diagnosis and treatment plans tailored to your specific clinical history.

Related Clinical Integration

In the modern clinical management of Lymphocytic Gastritis and its variant, Collagenous Gastritis, the diagnostic and therapeutic pathway relies on a precise integration of advanced endoscopic visualization and targeted pharmacological intervention. The Gastroscope (GIF-1TQ260 - Therapeutic) / منظار المعدة (GIF-1TQ260 - علاجي) serves as the primary instrument for obtaining high-quality mucosal biopsies necessary to confirm the characteristic intraepithelial lymphocytosis or subepithelial collagen deposition, while also allowing for the exclusion of secondary etiologies. Once a definitive diagnosis is established, particularly in symptomatic patients, the administration of Budesonide (MMX) / بوديزونيد (MMX) 9mg is frequently indicated as a first-line topical corticosteroid therapy to induce mucosal healing and effectively mitigate chronic inflammation within the gastric lining.